Delivery of cell cycle genes to block astrocytoma growth

Journal of Neuro-Oncology

Volumn 51, Issue 3, 2001, Pages 277-287

  Fueyo, J ^a   Gomez Manzano, C ^a   Liu, T J ^a   Yung, W K Alfred ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Astrocytoma; Cell cycle genes; P53; Rb; Therapy

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CYCLIN DEPENDENT KINASE INHIBITOR; FLAVOPIRIDOL; GELDANAMYCIN; HISTONE DEACETYLASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P16; PROTEIN P53; PROTEIN P63; PROTEIN P73; RAPAMYCIN; RETINOBLASTOMA PROTEIN; RETINOIC ACID; TRANSCRIPTION FACTOR E2F; VIRUS ONCOLYSATE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASTROCYTOMA; BIOMEDICAL ENGINEERING; CANCER CELL; CANCER INHIBITION; CELL AGING; CELL CYCLE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CHROMOSOME 10; CLINICAL TRIAL; DRUG SCREENING; DRUG TARGETING; GENE MUTATION; GENE TARGETING; GROWTH REGULATION; HUMAN; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REGULATORY MECHANISM; REVIEW; TUMOR SUPPRESSOR GENE; VIRUS MUTANT; VIRUS REPLICATION;

ANIMALS; ASTROCYTOMA; CELL CYCLE; CELL CYCLE PROTEINS; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; E2F1 TRANSCRIPTION FACTOR; GENE TRANSFER TECHNIQUES; GENES, P53; HUMANS; MULTIGENE FAMILY; PHOSPHORIC MONOESTER HYDROLASES; PTEN PHOSPHOHYDROLASE; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 0035000878     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1010661131403     Document Type: Review

References (90)

1. Alemany R, Gomez-Manzano C, Balague C, Yung WKA, Curiel DT, Kyritsis AP, Fueyo J: Gene therapy for gliomas: Molecular targets, adenoviral vectors, and oncolytic adenoviruses. Exp Cell Res 252: 1-12, 1999
2. Rasheed BK, Wiltshire RN, Bigner SH, Bigner DD: Molecular pathogenesis of malignant gliomas. Curr Opin Oncol 11: 162-167, 1999
3. Dirks PB, Rutka JT: Current concepts in neuro-oncology: the cell cycle - a review. Neurosurgery 40: 1000-1013, 1997
4. Nigro JM, Baker SJ, Preisinger AC: Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-708, 1989
5. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B: Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 355: 846-847, 1992
6. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993
7. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P: Mice lacking p21 CIP/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82: 675-684, 1995
8. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299, 1995
9. Buckbinder L, Talbott R, Valesco-Miguel S, Takenaka L, Faha B, Sezinger BR, Kley N: Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377: 646-649, 1995
10. Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang WW, Kruzel E, Radinsky R. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 15: 3032-3040, 1995
11. Wu GS, Saftig P, Peters C, El-Deiry WS: Potential role for cathepsin D in p53-dependent tumor suppression and chemosensitivity. Oncogene 16: 2177-2183, 1998
12. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B: A model for p53-induced apoptosis. Nature 389: 300-305, 1997
13. Caelles C, Helmberg A, Karin M: p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370: 220-223, 1994
14. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M: Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352: 345-347, 1991
15. Mercer WE, Shields MT, Amin M, Sauve GJ, Appella E, Romano JW, Ullrich SJ: Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci USA 87: 6166-6170, 1990
16. Rosenfeld MR, Meneses P, Dalmau J, Drobjnak M, Cordon-Cardo C, Kaplitt MG: Gene transfer of wild-type p53 results in restoration of tumor suppressor function in a medulloblastoma cell line. Neurology 45: 1533-1539, 1994
17. Merzak A, Raynal S, Rogers JP, Lawrence D, Pilkington GJ: Human wild-type p53 inhibits cell proliferation and elicits dramatic morphological changes in human glioma cell lines in vitro. J Neurol Sci 127: 125-133, 1994
18. Asai A, Miyagi Y, Sugiyama A, Gamanuma M, Hong SH, Takamoto S, Nomura K, Matsutani M, Takakura K, Kuchino Y: Negative effects of wild-type p53 and s-Myc on cellular growth and tumorigenicity of glioma cells. J NeuroOncol 19: 259-268, 1994
19. Van Meir EG, Roemer K, Diserens A-C, Kikuchi T, Rempel SA, Haas M, Huang HJ, Friedmann T, de Tribolet N, Cavenee WK: Single cell monitoring of growth arrest and morphological changes induced by transfer of wild-type p53 alleles to glioblastoma cells. Proc Natl Acad Sci USA 92: 1008-1012, 1995
20. Gomez-Manzano C, Fueyo J, Kyritsis AP, Steck PA, Roth JA, McDonnell TJ, Steck KD, Levin VA, Yung WK: Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res 56: 694-699, 1996
21. Gomez-Manzano C, Fueyo J, Kyritsis AP, McDonnell TJ, Steck PA, Levin VA, Yung WK: Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. J Natl Cancer Inst 14: 1036-1044, 1997
22. Agarwal MN, Agarwal A, Taylor WR, Stark GR: p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA 92: 8493-8497, 1995
23. Polyak K, Waldman T, He T-C, Kinzler KW, Vogelstein B: Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev 10: 1945-1952, 1996
24. Michalovitz D, Halevy O, Oren M: Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant p53. Cell 62: 671-680, 1990
25. Stewart N, Hicks GG, Paraskevas F, Mowat M: Evidence for a second cell cycle block at G2/M by p53. Oncogene 10: 109-115, 1995
26. Cross SM, Sanchez CA, Morgan CA, Schimke MK, Ramel S, Idzerda RL, Raskind WH, Reid BJ: A p53-dependent mouse spindle checkpoint. Science 267: 1353-1356, 1995
27. Vikhanskaya F, Erba E, D'Incalci M, Broggini M: Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53. Nucleic Acids Res 22: 1012-1017, 1994
28. Wang Y, Prives C: Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases. Nature 376: 88-91, 1995
29. Xiong Y, Hannon G, Zhang H, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of the cyclin kinases. Nature (London) 366: 701-704, 1993
30. Sarkaria JN, Busby EC, Tibbetts RS, Roos P, Taya Y, Karnitz LM, Abraham RT: Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 59: 4375-4382, 1999
31. Powell SN, DeFrank JS, Connell P, Eogan M, Preffer F, Dombkowski D, Tang W, Friend S: Differential sensitivity of p53- and p53+ cells to caffeine-induced radiosensitization and override of G2 delay. Cancer Res 55: 1643-1648, 1995
32. Maheswaran S, Englert C, Bennett P, Heinrich G, Haber DA: The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev 9: 2143-2156, 1995
33. Badie B, Drazan KE, Kramar MH, Shaked A, Black KL: Adenovirus-mediated p53 gene delivery inhibits 9 L glioma growth in rats. Neurol Res 17: 209-216.18, 1995
34. Badie B, Kramar MH, Lau R, Boothman DA, Economu JS, Black KL: Adenovirus-mediated p53 gene delivery potentiates the radiation-induced growth inhibition of experimental brain tumors. J Neuro-Oncol 37: 217-222, 1998
35. Kock H, Harris MP, Anderson SC, Machemer T, Hancock W, Sutjipto S, Wills KN, Gregory RJ, Shepard HM, Westphal M, Maneval DC: Adenovirus-mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo. Int J Cancer 67: 808-815, 1996
36. Lang FF, Yung WK, Raju U, Libunao F, Terry NH, Tofilon PJ: Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene. J Neurosurg 89: 125-132, 1998
37. Li H, Alonso-Vanegas M, Colicos MA, Jung SS, Lochmuller H, Sadikot AF, Snipes GJ, Seth P, Karpati G, Nalbantoglu J: Intracerebral adenovirus-mediated p53 tumor suppressor gene therapy for experimental human glioma. Clin Cancer Res 5: 637-642, 1999
38. Kaelin WG: The p53 gene family. Oncogene 18: 7701-7705, 1999
39. Henson JW, Schnitker BL, Correa KM, von Deimling A, Fassbender F, Xu HJ, Benedict WF, Yandell DW, Louis DN: The retinoblastoma gene is involved in malignant progression of astrocytomas Ann Neural 36: 714-721, 1994
40. Fueyo J, Gomez-Manzano C, Yung WK, Liu TJ, Alemany R, Bruner JM, Chintala SK, Rao JS, Levin VA, Kyritsis AP: Suppression of human glioma growth by adenovirus-mediated Rb gene transfer. Neurology 50: 1307-1315, 1998a
41. Jen J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, Willson JK, Kinzler KW, Vogelstein B: Deletion of p16 and p15 genes in brain tumors. Cancer Res 54: 6353-6358, 1994
42. Schmidt EE, Ichimura K, Reifenberger G, Collins VP: CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 54: 6321-6324, 1994
43. Giani C, Finocchiaro G: Mutation rate of the CDKN2 in malignant gliomas. Cancer Res 54: 6338-6339, 1994
44. Kyritsis AP, Zhang B, Zhang W, Xiao M, Takeshima H, Bondy ML, Cunningham JE, Levin VA, Bruner J: Mutations of the p16 gene in gliomas. Oncogene 12: 63-67, 1996
45. Costello JF, Berger MS, Huang H-JS, Cavenee WK: Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res 56: 2405-2410, 1996
46. Fueyo J, Gomez-Manzano C, Bruner JM, Saito Y, Zhang B, Zhang W, Levin VA, Yung WK, Kyritsis AP: Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas. Oncogene 13: 1615-1619, 1996a
47. Fueyo J, Gomez-Manzano C, Yung WKA, Clayman GL, Liu TJ, Bruner J, Levin VA, Kyritsis AP: Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene 12: 103-110, 1996b
48. Arap W, Nishikawa R, Furnari FB, Cavenee WK, Huang H-SS: Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res 55: 1351-1354, 1995
49. Chintala SK, Fueyo J, Gomez-Manzano C, Venkaiah B, Bjerkvig R, Yung WKA, Sawaya R, Kyritsis AP, Rao JS: Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro. Oncogene 15: 2049-2057, 1997
50. Sandig V, Brand K, Herwing S, Lukas J, Bartek J, Strauss M: Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat Med 3: 313-319, 1997
51. Quelle DE, Zindy F, Ashmun RA, Sherr CJ: Alternative reading frames of the INK4a tumor suppressor gene encode two unrealted proteins capable of inducing cell cycle arrest. Cell 91: 993-1000, 1995
52. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan KH, Vousden KH, Peters G: The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and mdm2. EMBO J 17: 5001-5014, 1998
53. De Stanchina E, McCurrach ME, Zindy F, Shieh SY, Ferbeyre G, Samuelson AV, Prives C, Roussel MF, Sherr CJ, Lowe SW: E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev 12: 2434-2442, 1998
54. Van den Heubel S, Harlow E: Distinct roles for cyclin-dependent kinases in cell cycle control. Science 262: 2050-2054, 1993
55. De Azevedo WF Jr, Mueller-Dieckmann HJ, Schulze-Gahmen U, Worland PJ, Sausville E, Kim SH: Structural basis for specificity and potency of a flavonoid inhibitor of human cdk2, a cell cycle kinase. Proc Natl Acad Sci USA 93: 2735-2740, 1996
56. Carlson B, Lahusen T, Singh S, Loaiza-Perez A, Worland PJ, Pestell R, Albanese C, Sausville EA, Senderowicz AM: Down regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res 59: 4634-4641, 1999
57. Meijer L: Chemical inhibitors of cyclin-dependent kinases. Trends Cell Biol 6: 393-397, 1996
58. Shapiro G, Wade HJ: Anticancer drug targets: cell cycle and checkpoint control. J Clin Invest 104: 1645-1653, 1999
59. Cinti C, Claudio PP, Howard CM, Neri LM, Fu Y, Leoncini L, Tosi GM, Maraldi NM, Giordano A: Genetic alterations disrupting the nuclear localization of the retinoblastoma-related gene Rb2/p130 in human tumor cell lines and primary tumors. Cancer Res 60: 383-389, 2000
60. Claudio PP, Howard CM, Baldi A, De Luca A, Fu Y, Condorelli G, Sun Y, Colburn N, Calabretta B, Giordano A: p130/Rb2 has growth suppressive properties similar to yet distinctive from those of retinoblastoma family members pRB and p107. Cancer Res 54: 5556-5560, 1994
61. Tenan M, Benedetti S, Fionocchiaro G: Deletion and trasfection analyses of the p15/MTS2 gene in malignant gliomas. Biochem Biophys Res Commun 217: 195-202, 1995
62. Chen J, Willingham T, Shuford M, Bruce D, Rushing E, Smith Y, Nisen PD: Effects of ectopic overexpression of p21 (WAF1/CIP1) on aneuploidy and the malignant phenotype of human brain tumor cells. Oncogene 13: 1395-1403, 1996a
63. Chen J, Willingham T, Shuford M, Nisen PD: Tumor suppression and inhibition of aneuploid cell accumulation in human brain tumor cells by ectopic overexpression of the cyclin-dependent kinase inhibitor p27Kip1. J Clin Invest 97: 1983-1988, 1996b
64. Simon M, Koster G, Menon AG, Scramm J: Functional evidence for a role of combined CDKN2A (p16-p14(ARF)/CDKN2B (p15) gene inactivation in malignant gliomas. Acta Neuropathol (Berl) 98: 444-452, 1999
65. Fueyo J, Gomez-Manzano C, Puduvalli VK, Martin-Duque P, Perez-Soler R, Levin VA, Yung WK, Kyritsis AP: Adenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan: implications for therapy. Int J Oncol 12: 665-669, 1998b
66. Fueyo J, Gomez-Manzano C, Yung WK, Liu TJ, Alemany R, McDonnell TJ, Shi X, Rao JS, Levin VA, Kyritsis AP: Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat Med 4: 685-690, 1998c
67. Jung J-M, Bruner JM, Ruan S, Langford LA, Kyritsis AP, Kobayashi T, Levin VA, Zhang W: Increased levels of p21WAF1/Cip1 in human brain tumors. Oncogene 11: 2021-2028, 1995
68. Dirks PB, Rutka JT, Hubbard SL, Mondal S Hamel PA: The E2F-family proteins induce distintc cell cycle regulatory factors in p16-arrested, U-343 astrocytoma cells. Oncogene 17: 867-876, 1998
69. DeGregori J, Leone G, Miron A, Jakoi L, Nevins JR: Distinct roles for E2F proteins in cell growth control and apoptosis. Proc Natl Acad Sci USA 94: 7245-7250, 1997
70. Chen YN, Sharma SK, Ramsey TM, Jiang L, Martin MS, Baker K, Adams PD, Bair KW, Kaelin WG Jr: Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci USA 96: 4325-4329, 1999
71. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang S, Pue J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science 275: 1943-1946, 1997
72. Steck PA, Pershouse MA, Jasser SA, Yung WKA, Lin H, Ligon AH, Lauren LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV: Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers . Nat Genet 15: 356-362, 1997
73. Cheney IW, Neuteboom ST, Vaillancourt MT, Ramachandra M, Bookstein R: Adenovirus-mediated gene transfer of MMAC1/PTEN to glioblastoma cells inhibits S phase entry by the recruitment of p27Kip1 into cyclin E/CDK2 complexes. Cancer Res 59: 2318-2323, 1999
74. Davies MA, Lu Y, Sano T, Fang X, Tang P, LaPushin R, Koul D, Bookstein R, Stokoe D, Yung WKA, Mills GB, Steck PA: Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induce anoikis. Cancer Res 58: 5285-5290, 1998
75. Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, Gottschalk AR, Ryan HE, Johnson RS, Jefferson AB, Stokoe D, Giaccia AJ: Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14: 391-396, 2000
76. Tamura M, Gu J, Danen EH, Takino T, Miyamoto S, Yamada KM: PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphadylinositol 3-kinase/Akt cell survival pathway. J Biol Chem 274: 20693-20703, 1999
77. Dyson N, Harlow E: Adenovirus E1A targets key regulators of cell proliferation. Cancer Surv 12: 161-195, 1992
78. Flint J, Shenk T: Viral transactivating proteins. Annu Rev Genet 31: 177-212, 1997
79. Nevins JR: E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 258: 424-429, 1992
80. Whyte P, Ruley HE, Harlow E: Two regions of the adenovirus early region 1A proteins are required for transformation. J Virol 62: 257-265, 1988
81. Whyte P, Williamsom NM, Harlow E: Cellular targets for transformation by the adenovirus E1A proteins. Cell 56: 67-75, 1989
82. Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, Shi YX, Levin VA, Yung WKA, Kyritsis AP: A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19: 2-12, 2000
83. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM: Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Science 10: 854-856, 1991
84. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL: Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 9: 938-943, 1995
85. Andreanski S, Soroceanu L, Flotte ER, Chou J, Market JM, Gillespie GY, Roizman B, Whitley RJ: Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res 57: 1502-1509, 1997
86. Chase M, Chung RY, Chiocca EA: An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat Biotechnol 16: 444-448, 1998
87. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274: 373-376, 1996
88. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH: ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3: 639-645, 1997
89. Freytag SO, Rogulski KR, Paielii DL, Gilbert JF, Kim JK: A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 9: 1323-1333, 1998
90. Kirn D, Hermiston T, McCormick F: ONYX-015: clinical data are encouraging. Nat Med 4: 1341-1342, 1998